March Factory New Orders Rise 1.5% Vs. Expected 0.6% Increase, Prior 0.3% Increase

TSX Now Up 20 Pts, Was Down 120 Pts Early Monday; Comes After Losses In 6 of Last 7 Full Sessions

Gyre Therapeutics Completes $300 Million All-Stock Acquisition of Cullgen

Gyre Therapeutics (GYRE) said Monday it closed the purchase of clinical-stage biopharmaceutical firm Cullgen through an all-stock transaction valued at roughly $300 million.The deal turns the acquired business into a wholly owned unit focusing on therapies for fibrosis and inflammatory diseases, the company said.Former Cullgen chief executive Ying Luo was appointed president, chief executive, and board member of the combined organization, while Ping Zhang will maintain his position as chairman of the board, Gyre Therapeutics said.Price: $7.97, Change: $+0.17, Percent Change: +2.18%

Update: Wedbush Raises Price Target on Advanced Micro Devices to $400 From $290, Keeps Outperform Rating

(Updates to include Wedbush's commentary).Wedbush raises Advanced Micro Devices (AMD) price target to $400 From $290 ahead of the upcoming Q1 earnings announcement, noting that the company is positioned to beat and guide higher on CPU strength.Continued demand for server compute should provide some insurance moving forward should GPU/AI revenues ramp more slowly than anticipated, analysts Matt Bryson and Antoine Legault wrote in a Monday note.Advanced Micro Devices has an average rating of overweight and mean price target of $312.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $345.87, Change: $-14.67, Percent Change: -4.07%